Lytix Biopharma AS

DB:6BG Stock Report

Market Cap: €23.9m

Lytix Biopharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:6BG Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 Dec 24Buy€6,902Kjetil HestdalIndividual13,500€0.51
16 Dec 24Buy€8,520Oystein RekdalIndividual16,666€0.51
16 Dec 24Buy€1,618,903Saturn Invest ASCompany3,166,666€0.51
16 Dec 24Buy€4,260Baldur SveinbjørnssonIndividual8,333€0.51
16 Dec 24Buy€8,520Gjest BreisteinIndividual16,666€0.51
16 Dec 24Buy€2,185Evelina VagesjoIndividual4,274€0.51

Insider Trading Volume

Insider Buying: 6BG insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 6BG?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders219,7670.443%
Institutions5,938,03412%
General Public13,079,25526.4%
Private Companies30,373,24761.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.

Top Shareholders

Top 25 shareholders own 73.59% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.5%
Citigroup Inc.,Banking and Securities Investments
4,711,409€2.3m0%no data
9.04%
Saturn Invest AS
4,485,579€2.2m240%no data
8.93%
Jakob Hatteland Holding AS
4,428,816€2.1m0%no data
5.62%
Taj Holding As
2,788,900€1.3m0%no data
4.92%
Lyr Invest As
2,438,863€1.2m0%no data
3.75%
Waatvika As
1,860,764€897.3k0%no data
3.65%
3T Produkter Holding AS
1,808,764€872.2k0%no data
3.45%
BrøDrene Karlsen Holding A/S
1,709,274€824.2k0%no data
3.05%
Per Strand Eiendom As
1,510,769€728.5k0%no data
2.81%
Ynni Invest As
1,392,889€671.7k0%no data
2.66%
Hifo Invest AS
1,318,913€636.0k0%no data
2.06%
Care Holding As
1,024,287€493.9k0%no data
1.81%
Lth Invest As
896,786€432.4k0%no data
1.8%
Kvasshøgdi AS
890,986€429.6k0%no data
1.53%
Belvedere AS
760,430€366.7k0%no data
1.49%
Jahatt AS
738,167€356.0k0%no data
1.4%
Picasso AS
695,753€335.5k0%no data
1.35%
Skandinaviska Enskilda Banken AB, Asset Management Arm
669,115€322.7k0%0.05%
1.24%
Lysnes Invest As
615,654€296.9k0%no data
1.12%
Norinnova Invest AS
557,510€268.8k0%no data
1.04%
North Murray AS
516,814€249.2k0%no data
0.99%
Dragesund Invest AS
490,839€236.7k0%no data
0.32%
Oystein Rekdal
156,629€75.5k11.9%no data
0.056%
Gjest Breistein
27,778€13.4k150%no data
0.027%
Kjetil Hestdal
13,500€6.5k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lytix Biopharma AS is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carl RamaniusRedeye